Reyna Huang

Ms. Reyna Huang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
KLKevin Lonabaugh
Kevin Lonabaugh
GLGalvin Li
Galvin Li
RLRhonda List
Rhonda List
RHReyna Huang
Reyna Huang
AJAmber James
Amber James
DADana Albon
Dana Albon
Introduction: The introduction of the highly effective modulator therapy elexacaftor‐tezacaftor‐ivacaftor (ETI) has revolutionized the care of persons with cystic fibrosis (PwCF) with major improvements seen in lung function and body mass index. The effects of ETI therapy in real‐world cohorts on other parameters such as cholesterol levels are largely unknown.Methods: A single‐center, retrospective chart review study was conducted to assess the change in lipid panels before and after ETI initiation. The study investigated total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), and triglyceride levels using both a univariate and multivariate mixed‐effects model to evaluate the change after initiation of ETI in a cohort of PwCF.Results: There were 128 adult PwCF included in the analysis. Statistically significant changes were seen in both univariate and multivariate analyses for TC, LDL‐C, and HDL‐C. On multivariate analysis, TC increased by an average of 15.0 mg/dL after ETI initiation (p < 0.0001), LDL‐C increased by an average of 9.3 mg/dL (p < 0.001), and HDL‐C increased by an average of 3.8 mg/dL (p < 0.001) after ETI initiation.Conclusion: In this real‐world cohort of PwCF, cholesterol parameters increased after initiation with ETI therapy. Further consideration may need to be given for PwCF in regards to screening for cardiometabolic risk factors as PwCF age as well as the potential need for cholesterol‐lowering therapies.

14 December 2017 in Genes
Verified
Journal Article
Open access
PDF file
RHReyna Huang
Reyna Huang
SKShailesh Kumar
Shailesh Kumar
HLHui Li
Hui Li
Chimeric RNAs have been recognized as a phenomenon not unique to cancer cells. They also exist in normal physiology. Aging is often characterized by deregulation of molecular and cellular mechanisms, including loss of heterochromatin, increased transcriptional noise, less tight control on alternative splicing, and more stress-induced changes. It is thus assumed that chimeric RNAs are more abundant in older people. In this study, we conducted a preliminary investigation to identify any chimeric RNAs with age-based trends in their expression levels in blood samples. A chimeric RNA candidate list generated by bioinformatic analysis indicated the possibility of both negative and positive trends in the expression of chimeric RNAs. Out of this candidate list, five novel chimeric RNAs were successfully amplified in multiple blood samples and then sequenced. Although primary smaller sample sizes displayed some weak trends with respect to age, analysis of quantitative PCR data from larger sample sizes showed essentially no relationship between expression levels and age. Altogether, these results indicate that, contradictory to the common assumption, chimeric RNAs as a group are not all higher in older individuals and that placing chimeric RNAs in the context of aging will be a much more complex task than initially anticipated.

7 January 2025 in Pediatric Pulmonology
Verified
Journal Article
Open access
RHReyna Huang
Reyna Huang
MSMatthew T. Snyder
Matthew T. Snyder
NFNuzhat Fahmida
Nuzhat Fahmida
DADana P. Albon
Dana P. Albon
Introduction: While the diagnosis of cystic fibrosis (CF) is often straightforward and reliant on correlation between genetic testing and clinical signs and symptoms, there is a subset where the distinction is not nearly as clearcut. This has previously been reported in patients identified through newborn screening but not meeting full CF diagnostic criteria, earning the label of CF Screen Positive, Inconclusive Diagnosis (CFSPID) instead. A homologous diagnostic category in adults is named CF Transmembrane Conductance Regulator‐Related Disorder (CFTR‐RD). Methods: Through a retrospective chart review, this study reports on a relatively large adult cohort ( n = 23) that presented to pulmonology clinic at a single center with intermediate or positive sweat chloride tests but non‐diagnostic full CFTR gene analysis. Results: Median sweat chloride result was 48 mmol/L, and a majority of the cohort had chronic lung disease with atypical pathogens on sputum culture, including Pseudomonas aeruginosa, non‐tuberculous Mycobacteria, Acinetobacter species, amongst others. Conclusions: This clinical picture suggests CFTR dysfunction or similar mechanism in the absence of an identified genetic cause. Alternate chloride channels and their respective genes or candidates of genetic modifiers to the CF‐phenotype could be targets of further research in this cohort or similar patients. Such genetic modifiers include loci that have been implicated in inflammation, the CFTR interactome, and/or co‐/post‐translational modification of CFTR.

4 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
PDPrecilla D’souza
Precilla D’souza
CFCristan Farmer
Cristan Farmer
JJJean Johnston
Jean Johnston
SHSangwoo T Han
Sangwoo T Han
DADavid Adams
David Adams
CTCynthia J Tifft
Cynthia J Tifft
Purpose: GM1 gangliosidosis (GM1) is an ultra-rare lysosomal storage disease caused by pathogenic variants in galactosidase beta 1 ( GLB1 ; NM_000404), primarily characterized by neurodegeneration, often in children. There are no approved treatments for GM1, but clinical trials using gene therapy ( NCT03952637 , NCT04713475 ) and small molecule substrate inhibitors ( NCT04221451 ) are ongoing. Understanding the natural history of GM1 is essential for timely diagnosis, facilitating better supportive care, and contextualizing the results of therapeutic trials. Methods: Forty-one individuals with type II GM1 (n=17 late infantile and n=24 juvenile onset) participated in a single-site prospective observational study. Here, we describe the results of extensive multisystem assessment batteries, including clinical labs, neuroimaging, physiological exams, and behavioral assessments. Results: Classification of 37 distinct variants in this cohort was performed according to ACMG criteria and resulted in the upgrade of six and the submission of four new variants to pathogenic or likely pathogenic. In contrast to type I infantile, children with type II disease exhibited normal or near normal hearing and did not have cherry red maculae or significant hepatosplenomegaly. Some older children with juvenile onset developed thickened aortic and/or mitral valves with regurgitation. Serial MRIs demonstrated progressive brain atrophy that were more pronounced in those with late infantile onset. MR spectroscopy showed worsening elevation of myo-inositol and deficit of N -acetyl aspartate that were strongly correlated with scores on the Vineland Adaptive Behavior Scale and progress more rapidly in late infantile than juvenile onset disease. Conclusion: The comprehensive serial phenotyping of type II GM1 patients expands the understanding of disease progression and clarifies some common misconceptions about type II patients. Findings from this 10-year endeavor are a pivotal step toward more timely diagnosis and better supportive care for patients. The wealth of data amassed through this effort will serve as a robust comparator for ongoing and future therapeutic trials.